Direct costs of illness of patients with chronic cough in rural Malawi—Experiences from Dowa and Ntchisi districts
Authors:
Junious M. Sichali aff001; Jahangir A. K. Khan aff002; Elvis M. Gama aff002; Hastings T. Banda aff001; Ireen Namakhoma aff001; Grace Bongololo aff001; Rachael Thomson aff002; Berthe Stenberg aff003; S. Bertel Squire aff002
Authors place of work:
Research for Equity and Community Health (REACH) Trust, Lilongwe, Malawi
aff001; Centre for Applied Health Research and Delivery (CAHRD), Liverpool School of Tropical Medicine, Liverpool, United Kingdom
aff002; LHL’s International Tuberculosis Foundation (LHL International), Oslo, Norway
aff003
Published in the journal:
PLoS ONE 14(12)
Category:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0225712
Summary
Introduction
Chronic cough is a distressing symptom and a common reason for people to seek health care services. It is a symptom that can indicate underlying tuberculosis (TB) and/or chronic airways diseases (CAD) including asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. In developing countries including Malawi, provision of diagnostic services and clinical management of CAD is rudimentary, so it is thought that patients make costly and unyielding repeated care-seeking visits. There is, however, a lack of information on cost of illness, both direct and indirect, to patients with chronic cough symptom. Such data are needed to inform policy-makers in making decisions on allocating resources for designing and developing the relevant health care services to address universal coverage programmes for CAD. This paper therefore explores health seeking costs associated with chronic cough and explores information on usage of the coping mechanisms which indicate financial hardship, such as borrowing and selling household assets.
Methods
This economic study was nested within a community-based, population-proportional cross-sectional survey of 15,795 individuals aged 15 years and above, in Dowa and Ntchisi districts. The study sought to identify individuals with symptoms of chronic airways disease whose health records documented at least one of the following diagnoses within the previous year: TB, Asthma, COPD, Bronchitis and Lower Respiratory Tract Infection (LRTI). We interviewed these chronic coughers to collect information on socioeconomic and socio-demographic characteristics, health care utilization, and associated costs of care in 2015. We also collected information on how they funded their health seeking costs.
Results
We identified 608 chronic coughers who reported costs in relation to their latest confirmed diagnosis in their hand-held health record. The mean care-seeking cost per patient was US$ 3.9 (95% CI: 3.00–5.03); 2.3 times the average per capita expenditure on health of US$ 1.69. The largest costs were due to transport (US$ 1.4), followed by drugs (US$ 1.3). The costs of non-medical inputs (US$ 2.09) was considerable (52.3%). Nearly a quarter (24.4%) of all the patients reportedly borrowed or/and sold assets/property to finance their healthcare. CCs with COPD and LRTI had 85.6% and 62.0% lower chance of incurring any costs compared with the TB patients and any patients with comorbidity had 2.9 times higher chance to incur any costs than the patients with single disease. COPD, Bronchitis and LRTI patients had 123.9%, 211.4% and 87.9% lower costs than the patients with TB. The patients with comorbidity incurred 53.9% higher costs than those with single disease.
Conclusions
The costs of healthcare per chronic cougher was mainly influenced by the transport and drugs costs. Types of diseases and comorbidity led to significantly different chances of incurring costs as well as difference in magnitude of costs. The costs appeared to be unaffordable for many patients.
Keywords:
Health economics – Diagnostic medicine – tuberculosis – Socioeconomic aspects of health – chronic obstructive pulmonary disease – Coughing – Asthma – Psychological defense mechanisms
Introduction
Tuberculosis and chronic airway diseases (CAD) including asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis represent a major disease burden to most developing countries, particularly in Sub-Saharan Africa [1–4]. COPD and asthma are estimated to affect 64 million and 235 million people worldwide, respectively [3]. A diagnosis for people with chronic or persistent cough is usually delayed because of individual and health system barriers. Unfortunately, delayed diagnosis and treatment of TB, COPD and asthma facilitates further TB transmission, severity of disease with complications and increased mortality. In the latest estimates by World Health Organisation, COPD was the fourth leading cause of deaths in 2004, and in 2030, it is projected to become the third leading cause, with 5.8 million or 8.6% of the total deaths [3].
It has been estimated that, asthma morbidity and mortality accounts for around 1% of all disability-adjusted life years (DALYs), equivalent to 16 million DALYs lost per year worldwide [3]. A crucial point is that all respiratory diseases, if not diagnosed, treated and managed promptly and correctly, are problematic for individuals and health systems alike [5].
Furthermore, COPD is characterized by airflow limitation that is not fully reversible but nonetheless treatable. The World Health Organization (WHO) estimates that 65 million people have moderate to severe COPD with 5% of all (3 million) global deaths being attributed to COPD [6]. About 90% of these COPD deaths occur in low-income and middle-income countries. At the other end of the spectrum, asthma, a chronic inflammatory disorder of the airways, is characterized by episodes of reversible breathing problems (that may be life-threatening) due to airway narrowing and obstruction. These episodes are characterized by coughing, wheezing, chest tightness and shortness of breath. The frequency and severity of these episodes can have a marked impact on the livelihoods and the well-being of those affected [7]. Bronchiectasis is a severe, chronic infection of the lung associated with permanent abnormal dilatation of bronchi [8]. As a result, mucus clearance is impaired, leading to accumulation of secretions, bacterial overgrowth and recurrent infections.
Health seeking costs associated with chronic cough (CC) are estimated to rank as one of the highest among chronic diseases due to the significant health care utilisation associated with these conditions [9,10]. Severe and poorly controlled chronic cough is believed to have a high economic burden both directly (hospitalisation, diagnostic tests and medicines) and indirectly (productivity loss) [9–12]. In addition, chronic cough is also associated with the loss of future potential earnings related to morbidity and mortality. `
Numerous studies have been published evaluating health seeking costs of CC in high income countries [13–16, 17] however, a dearth of evidence exists on similar studies in low income countries [9, 18–20]. In order to address the major CC challenges that threaten health and economies alike in low income settings, it is important to have information on the type and extent of costs incurred by different groups of individuals affected by chronic cough [9, 21–25].
This is important given that in low income settings, relatively small costs on health can be disastrous and lead to catastrophic healthcare expenditure [10–12]. This implies that the cost of regular chronic cough diagnosis and treatment could be unaffordable to families in low income settings. One challenge that policy makers face is the lack of cost data to inform the design and provision of universal coverage programs for core health service responses to chronic cough [9, 10 and 12]
Objectives
The main objective of this paper is to explore health seeking costs incurred by chronic coughers starting from the onset of symptoms, to diagnosis and the management of the illness. This is the cost of the whole care-seeking process which includes pre-diagnostics and diagnostic costs, treatment costs, hospitalisation costs as well as guardians (accompanied persons) costs. To reach the main objective, we set out to estimate the direct costs (medical and non-medical) associated with chronic cough, estimate variations in these costs across socio-economic and socio-demographic groups and to identify coping mechanisms with detrimental effects on economic status of the chronic coughers.
Methods
Study design
This study was reviewed and approved by The College of Medicine Research and Ethics Committee (COMREC), which is situated within The University of Malawi, College of Medicine. This is a local Institutional Review Board which approves research projects in Malawi. This was a trial with the following approval number: P.07/13/1424 [17]. Participants signed consent forms after agreeing to participate in the study on the basis of information provided by the data collectors. For those less than 18 years, we obtained consent from parents first, before seeking their individual consent and they signed consent form afterwards.
This cross-sectional community-based survey was conducted in 2015 (January to June) in rural areas of two districts, namely, Dowa and Ntchisi, in the central region of Malawi. A total of 15,795 individuals were included in the survey where household was the unit of approach. Among other goals, this survey intended to identify individuals at age 15 years and above with evidence or symptoms of chronic cough/wheeze, and a diagnosis in their health passport. It was also intended to collect data on health seeking costs that chronic coughers incur before getting a diagnosis, after diagnosis, treatment, hospitalisation as well as guardian costs and how health seeking costs incurred by chronic coughers were financed. i.e. financial coping mechanisms.
Data collection
We administered a validated patient cost questionnaire recommended by the Stop TB Partnership [26] using pre-programmed smartphones. These participants were selected because they reported costs in relation to their latest confirmed diagnosis through health card/passport. Participants with chronic cough were asked to detail their costs including out-of-pocket medical expenditure (for example administration fees, charges for tests, cost of travel to health facilities and food during a long trip and at the health facility) and coping mechanisms (money they borrowed or received from selling assets to cover the cost of diagnosis).
Data analysis
Data analysis was done in STATA v13.1. Direct medical and non-medical costs associated with chronic cough were summarised using means accompanied by their 95% confidence intervals. An estimate of variations in costs based on socio-demographic and socio-economic status was done by looking at how much each category (age, sex, education level and occupation) of chronic coughers paid to access healthcare. For coping mechanisms, we calculated the absolute number of chronic coughers who sold assets and/or borrowed money to finance health seeking costs. Costs were reported in United States Dollar (US$) using April 2015 exchange rate (US$1 = MK450) from OANDA—https://www.oanda.com/currency/converter/. We collected information on how much was spent for the preceding 12 months at the time of the survey for the utilized health services e.g., pre-diagnostics and diagnostic costs, treatment costs, hospitalisation costs as well as guardian costs. The specific items costed include administrative, laboratory, X-ray, drugs, travel, food as well as accommodation.
Two-part regression analysis was applied to estimate the effect of individuals’ sociodemographic characteristics on the direct healthcare costs for seeking healthcare due to chronic cough. The direct costs was a limited dependent variable and was continuous over most of its distribution but had a mass of observations at zero values. The decision of spending for healthcare and its magnitude might not be statistically independent [27, 28] Applying an Ordinary Least Square (OLS) estimation method of regression coefficient to only those individuals who spent for healthcare might result in selection bias [28]. We thus applied a two-part regression model [27, 29]. The first part estimated the likelihood of incurring any healthcare costs, where 0 meant ‘no cost’ and 1 meant ‘any incurred cost’. This was incorporated in the two-part model with a logit function. The second part considered the magnitude of the direct healthcare costs. An ordinary least square function was applied to predict it. Thus the two-part model used information on both the probability and magnitude of direct costs for healthcare simultaneously in assessing the effects of sociodemographic factors of the individuals [30, 31].
Results
Health care costs
There were a total of 608 people, with confirmed diagnosis of CAD in their health card/passport who reported costs in relation to their health care seeking, with a total mean cost of US $3.9 as illustrated in Table 1.
Table 1 above provides an overview of the mean costs and 95% confidence intervals by type of direct costs, both medical and non-medical. These costs have been disaggregated into administration, diagnostic tests, X-ray, drugs, transport, food and accommodation for chronic coughers with a confirmed diagnosis in their health passport. Of the total costs incurred by chronic coughers, drugs and transport form the largest part of the expenditure as evidenced by US$ 1.3 and US$ 1.4 respectively. We have compared the health care costs of chronic coughers with the household consumption expenditure in rural Malawi. According to the Malawi Integrated Household Survey of 2010/11, the annual per capita consumption of US$ 107.4 or per household US$ 494 considering the average household size of 4.6 and inflation rate of 23.4% per year during 2012–15 [32, 33]. Our estimated health care costs (US$ 3.9) of chronic coughers thus constituted 0.42% of household consumption expenditure. The mean cost was compared against the household consumption expenditure because we wanted to see how much of the total household consumption expenditure goes to health care seeking.
The magnitude of costs was also dependent on the kind of diagnoses such that some diseases were costlier than others. For instance, Table 2 shows that TB patients incurred the largest average costs ($10.5), followed by the patients with comorbidity ($ 9.4) and Asthma ($ 6.9) respectively. High costs were a result of transport which patients incur in the course of seeking diagnosis and getting treatment but also drugs.
Further analysis shows that there were also variations in costs incurred by chronic coughers with respect to symptoms such that those with breathlessness paid slightly higher costs than those with other symptoms as seen from Table 3.
It was also observed that there were variations in costs with respect to sociodemographic and socioeconomic conditions of the chronic coughers (Table 4). The results showed that men had higher costs (US$ 4.2) than women (US$ 3.9), but the difference was not statistically significant. This difference can also be explained by the fact that most women have less money to spend as such they cannot afford the higher health care seeking costs. However, health seeking costs increased with age such that those aged 65 and above incurred higher costs (US$ 6.5) than those aged below 65 years. Marital status was also a cost determinant such that widows incurred higher cost (US$ 5.5) than those who are married (US$ 4.2) and divorced (US$ 3.1).
Most chronic coughers who reported health seeking costs had primary level education and their cost was slightly higher than those without any formal education and those with secondary education and above (Table 5). Most of them were farmers while some were casual workers, civil servants and the private sector. Civil servants and private sector employees had higher costs, though not statistically significant, than any other occupations probably because they can afford to access health care from the private hospitals which is usually expensive.
Our two-part multiple regression model found that the presence of diseases and comorbidity led to significantly higher chance of incurring any healthcare costs (stage 1 in Table 6). CCs with COPD and LRTI had 85.6% and 62.0% lower change of incurring any costs compared with the TB patients. Further, any patients with comorbidity had 2.9 times higher chance to incur any costs than the patients with single disease. Stage 2 of the regression model (Table 6) showed that among those who had any healthcare costs, COPD and LRTI patients had 123.9%, 211.4% and 87.9% lower costs than the patients with TB. The patients with comorbidity incurred 53.9% higher costs than those with single disease.
We, further found that the individuals with occupational attachment to civil service and private sectors had significantly higher costs (88.9%) than the farmers. No other socioeconomic or demographic factors showed any significant influence on costs for healthcare of the CCs.
Financial coping mechanisms
In addition to income and savings, two major coping mechanisms for health care payments were observed, namely borrowing and selling assets/properties. Our findings in Table 7 below show that some chronic coughers borrowed money from various sources while others sold something including household assets. Most borrowing came from the neighbours (41%) followed by borrowing from family members (33%) and very few (6%) through bank loans.
Most chronic coughers sold household assets to cover health care costs and the majority of costs came from selling farm products (58.8%) and livestock (30.4%). See Table 6 above.
Discussion
A total of 608 chronic coughers reported health care costs in relation to their latest illnesses and the mean total cost was estimated to be US$ 3.9 in a 12-month period. The largest share of these costs was due to transport (US$ 1.4), followed by medicines (US$1.3). Considering that the majority of the population where the study was done is poor, the 0.42% of the total household consumption expenditure is a huge burden. The variations in costs could be described by demographic and socioeconomic characteristics of the investigated chronic coughers. We observed that chronic coughers at age of 65 years and above had the largest costs which reduced with younger ages. This was probably due to the fact that most elderly people required a guardian to go to the health facility where they sought health care and the costs drove upwards mainly due to transport, food and accommodation. We also noted that the costs were higher for widows (US $5.5) than those who were married, divorced/separated and those who had never been married. However, no clear reasons of such disparities could be identified. Our multivariate analysis showed that patients with different diseases had significantly different chance of incurring healthcare costs and that costs varied depending on the type of diseases and well as the presence of comorbidity.
Our findings, however, were consistent with previous studies, which investigated chronic coughers’ pathways to seeking health care and the associated costs they incurred in other low-income settings [1,21,23,25]. As in Uganda, most chronic cough patients followed a complex pathway, including herbalist, informal providers and formal providers [9]. According to our findings and those of previous studies, this complex pathway often resulted in repeated visits to the providers, which possibly contributed to increasing health care costs.
We do not have scope of estimating the incidence of catastrophic costs of households due to limitation of data particularly on household income or consumption expenditure. However, using a proxy measurement of financial protection, this study confirmed that many chronic coughers sold assets/property and borrowed money to pay for health care. Such findings gave an indication that the costs of care, even if not very high in absolute terms, were not affordable for many poor households and might have brought economic impoverishment to some on a temporary basis if it was not persistent.
We were aware of a limitation of this study regarding recall bias. We used a cross-sectional survey covering a 12-month period, which might be subject to recall bias while our main variables of interest dealt with costs of healthcare. Although the bias might be low with the reported costs of the current visits, we suspect that the costs of previous visits might suffer more from this recall bias.
Despite this limitation, the study does present important insights into health seeking costs of chronic coughers and illuminates some coping mechanisms that can cause or perpetuate poverty. First, while selling of assets can help raise money to cover chronic cough related expenses, it is important to note that asset sale involving disposal of factors of production like land may increase the vulnerability of households. Second, borrowing money from family, friends or money- lenders may represent a reasonable trade-off overtime. However, they can increase the economic vulnerability of households in the long term, particularly for large health seeking costs [34].
We propose that further studies on costs of chronic coughers should be done so that costing data can inform policy makers in the design and provision of universal coverage programs for core chronic cough health services. Future studies should also look at management of CAD and TB in relation to cost implication. Addressing major chronic cough challenges that threaten health and economies alike in low-income settings requires information on the type and extent of costs incurred by different groups (income groups, geographic regions etc.) of individuals affected by chronic cough, which can contribute with more knowledge than that found by this current study. The results from the current study, however, can add to the knowledge of the policy makers in designing and provision of universal coverage programs for core chronic cough health services [9, 10 and 12]
Conclusion
The costs of healthcare per chronic cougher was mainly influenced by the costs of transport and drugs and these costs varied with demographic and socioeconomic characteristics of the patients. Types of diseases and comorbidity led to significantly different chances of incurring costs and the magnitude of costs varied significantly. Though the costs were not reportedly very high as a share of total household consumption expenditure, it appeared to be unaffordable for many patients.
Supporting information
Zdroje
1. Aikins AG, Unwin N, Agyemang C, Allotey P, Campbell C, Arhinful D. Tackling Africa’s chronic disease burden: from the local to the global. Glob Health. 2010;6:5.
2. Martins P, Rosado-Pinto J, do Céu Teixeira M, Neuparth N, Silva O, Tavares H, et al. Under-report and under diagnosis of chronic respiratory diseases in an African country. Allergy. 2009;64:1061–7. doi: 10.1111/j.1398-9995.2009.01956.x 19210360
3. World Health Organization: The Global Burden of Disease: 2004 Update. WHO; 2008
4. Stanciole AE, Ortegón M, Chisholm D, Lauer JA. Cost effectiveness of strategies to combat chronic obstructive pulmonary disease and asthma in Sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012;344:e608. doi: 10.1136/bmj.e608 (Published 2 March 2012). 22389338
5. Van den Boom M, Seita A, Ottmani S, Migliori GB. Finding the way through the respiratory symptoms jungle: PAL can help. Eur Respir J. 2010;36:979–82. doi: 10.1183/09031936.00116810 21037364
6. WHO. Burden of COPD. http://www.who.int/respiratory/copd/burden/en/ Accessed May 20–21 2013.
7. Mathers CD, Lopez AD, Murray CJL. The burden of disease and mortality by condition: data, methods, and results for 2001. In: Lopez AD, Mathers CD, Ezzati M, et al., editors. Global burden of disease and risk factors. Washington (DC): World Bank; 2006. Chapter 3. http://www.ncbi.nlm.nih.gov/books/nbk11808 (accessed 22 May 2013).
8. Jordan TS, Spencer EM, Davies P. Tuberculosis, bronchiectasis, and chronic airflow obstruction. Respiralogy. 2010;16: 623–628.
9. Shete P.B. Haguma P. Miller C.R. Ochom E. Ayakaka I., Davis, et al, 2015. Pathways and costs of care for patients with tuberculosis symptoms in rural Uganda. The International Journal of Tuberculosis and Lung Disease, 19(8), pp.912–917. doi: 10.5588/ijtld.14.0166 26162356
10. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lonnroth K. Financial burden for tuberculosis patients in low- and middleincome countries: a systematic review. Eur Respir J 2014; 43: 1763–1775 doi: 10.1183/09031936.00193413 24525439
11. Bahadori K., Doyle-Waters M.M., Marra C., Lynd L., Alasaly K., Swiston J. et al 2009. Economic burden of asthma: a systematic review. BMC pulmonary medicine, 9(1), p.1.
12. Madan J., Lönnroth K., Laokri S. and Squire S.B., 2015. What can dissaving tell us about catastrophic costs? Linear and logistic regression analysis of the relationship between patient costs and financial coping strategies adopted by tuberculosis patients in Bangladesh, Tanzania and Bangalore, India. BMC health services research, 15(1), p.1.
13. Blanchette C.M., Roberts M.H., Petersen H., Dalal A.A. and Mapel D.W., 2011. Economic burden of chronic bronchitis in the United States: a retrospective case-control study. Int J Chron Obstruct Pulmon Dis, 6, pp.73–81. doi: 10.2147/COPD.S15882 21311695
14. Accordini S., Corsico A., Cerveri I., Gislason D., Gulsvik A., Janson C., et al 2008. The socio-economic burden of asthma is substantial in Europe. Allergy, 63(1), pp.116–124. doi: 10.1111/j.1398-9995.2007.01523.x 18053021
15. Guarascio A.J., Ray S.M., Finch C.K. and Self T.H., 2013. The clinical and economic burden of chronic obstructive pulmonary disease in the USA.ClinicoEconomics and outcomes research: CEOR, 5, pp.235–245.
16. Menzin J., Boulanger L., Marton J., Guadagno L., Dastani H., Dirani R. et al 2008. The economic burden of chronic obstructive pulmonary disease (COPD) in a US Medicare population. Respiratory medicine, 102(9), pp.1248–1256. doi: 10.1016/j.rmed.2008.04.009 18620852
17. Banda HT, Mortimer K, Bello GA, Mbera GB, Namakhoma I, Thomson R, et al, 2015, Informal Health Provider and Practical Approach to Lung Health interventions to improve the detection of chronic airways disease and tuberculosis at primary care level in Malawi: study protocol for a randomised controlled trial. Trials. 2015 Dec 17; 16:576. http://www.ncbi.nlm.nih.gov/pubmed/26679768
18. Abegunde D.O., Mathers C.D., Adam T., Ortegon M. and Strong K., 2007. The burden and costs of chronic diseases in low-income and middle-income countries. The Lancet, 370(9603), pp.1929–1938.
19. Ramsay A, Al-Agbhari N, Scherchand J, Al-Sonboli N, Almotawa A, Gammo M, et al. Direct patient costs associated with tuberculosis diagnosis in Yemen and Nepal. Int J Tuberc Lung Dis. 2010; 14(2):165–70. 20074407
20. Barter DM, Agboola SO, Murray MB, Barnighausen T. Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa: a systematic review. BMC Public Health 2012; 12: 980 doi: 10.1186/1471-2458-12-980 23150901
21. Ukwaja KN, Modebe O, Igwenyi C, Alobu I. The economic burden of tuberculosis care for patients and households in Africa: a systematic review. Int J Tuberc Lung Dis 2012; 16: 733–739. doi: 10.5588/ijtld.11.0193 22410546
22. Laokri S, Amoussouhui A, Ouendo EM, et al. A care pathway analysis of tuberculosis patients in Benin: highlights on direct costs and critical stages for an evidence-based decision-making. PLOS ONE 2014; 9: e96912. doi: 10.1371/journal.pone.0096912 24810007
23. Laokri S., Dramaix-Wilmet M., Kassa F., Anagonou S. and Dujardin B., 2014. Assessing the economic burden of illness for tuberculosis patients in Benin: determinants and consequences of catastrophic health expenditures and inequities. Tropical Medicine & International Health, 19(10), pp.1249–1258.
24. Sekandi J.N., Dobbin K., Oloya J., Okwera A., Whalen C.C. and Corso P.S., 2015. Cost-effectiveness analysis of community active case finding and household contact investigation for tuberculosis case detection in urban Africa. PloS one, 10(2), p.e0117009. doi: 10.1371/journal.pone.0117009 25658592
25. Lawson L., Al-Sonboli N., Al-Aghbari N., Arbide I., Sherchand J.B., Nnamdi, et al., 2016. Patients direct costs to undergo TB diagnosis. Infectious Diseases of Poverty, 5(1), p.1.
26. STOP TB Partnership, 2008, The tool to estimate patients’ costs, http://www.stoptb.org/wg/dots_expansion/tbandpoverty/assets/documents/Tool%20to%20estimate%20Patients'%20Costs.pdf
27. Okunade AA, Suraratdecha C, Benson DA. Determinants of Thailand household healthcare expenditure: the relevance of permanent resources and other correlates. Health Econ. 2010;19(3):365–376. doi: 10.1002/hec.1471 19405046
28. Jones A. A double-hurdle model of cigarette consumption. J Appl Econom. 1989;4(1):23–39.
29. Khan JAM, Ahmed S, Sultana M, Sarker AR, Chakrovorty S, Rahman MH, et al. 2019. The effect of a Community-Based Health Insurance on the Out-of-pocket Payments for Utilizing Medically Trained Providers in Bangladesh, Int Health [In press]
30. O’Donnell O, van Doorslaer E, Wagstaff A, Lindelow M. Analyzing Health Equity Using Household Survey Data: A Guide to Techniques and Their Implementation. Washington DC: The World Bank; 2008.
31. Cragg J. Some statistical models for limited dependent variables with application to the demand for durable goods. Econom J Econom Soc. 1971;39(5):829–844. http://www.jstor.org/stable/10.2307/1909582. Accessed January 10, 2014.
32. Malawi National Statistics Office, Integrated Household Survey(HIS) 2010-2011- Household Socio-economic characteristic report, 2012, Zomba, Malawi, http://www.nsomalawi.mw/images/stories/data_on_line/economics/ihs/IHS3/IHS3_Report.pdf
33. United Nations Statistics, Classification of Individual Consumption according to Purpose (COICOP)-Extract http://www.ilo.org/public/english/bureau/stat/download/cpi/coicop.pdf
34. Kruk M.E., Goldmann E. and Galea S., 2009. Borrowing and selling to pay for health care in low-and middle-income countries. Health Affairs, 28(4), pp.1056–1066. doi: 10.1377/hlthaff.28.4.1056 19597204
Článek vyšel v časopise
PLOS One
2019 Číslo 12
- Řekněte mi, co jíte, a já vám řeknu, jaká je úroveň vaší kognice
- Původní český test ALBA pro odhalení mírných kognitivních deficitů získal certifikaci MZ ČR
- Duševní onemocnění se u teenagerů přenáší v rámci školní třídy
- Od kostiček k lidské kůži. Jak si postavit 3D biotiskárnu?
- Prof. Libor Grubhoffer: Nová varianta mpox je příležitostí pokročit v poznání původce varioly
Nejčtenější v tomto čísle
- Methylsulfonylmethane increases osteogenesis and regulates the mineralization of the matrix by transglutaminase 2 in SHED cells
- Oregano powder reduces Streptococcus and increases SCFA concentration in a mixed bacterial culture assay
- The characteristic of patulous eustachian tube patients diagnosed by the JOS diagnostic criteria
- Parametric CAD modeling for open source scientific hardware: Comparing OpenSCAD and FreeCAD Python scripts
Zvyšte si kvalifikaci online z pohodlí domova
Všechny kurzy